{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:03:38Z","timestamp":1783721018189,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To systematically review and analyze existing literature reporting changes in choroidal thickness at 1, 3, 6, and 12 months following anti-VEGF treatment in patients with retinal vein occlusion (RVO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search identified 16 eligible studies including a total of 545 patients and 547 eyes. Data were extracted on subfoveal choroidal thickness at baseline and at specified follow-up intervals. Meta-analyses were performed to assess pooled changes in choroidal thickness after treatment, and subgroup analyses were conducted based on anti-VEGF drug type and treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 1- and 3-month follow-up, anti-VEGF therapy was associated with a significant reduction in choroidal thickness. By 12 months, choroidal thickness tended to return toward baseline levels, suggesting potential stabilization or structural adaptation. Subgroup analyses indicated that the effects on choroidal thickness may vary among different anti-VEGF agents, with ranibizumab and aflibercept showing significant early reductions, while bevacizumab demonstrated more delayed effects. Further subgroup analyses based on RVO type showed that at 1 month, choroidal thickness was significantly reduced in branch retinal vein occlusion patients, but not in central retinal vein occlusion patients, suggesting potential differences in drug response between RVO subtypes. However, given the limited number of studies within some subgroups, these findings should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with RVO, anti-VEGF therapy appears to induce an early reduction in choroidal thickness, which tends to return toward baseline with longer follow-up. Subgroup analyses provided preliminary insights into the potential influence of different agents, disease subtypes, and treatment regimens. However, this study was limited by the small number of eligible studies and the heterogeneity of study designs. Therefore, the findings should be regarded as exploratory and interpreted with caution. Future prospective studies with larger sample sizes, standardized imaging protocols, and longer follow-up are needed to clarify the clinical relevance of choroidal thickness changes in RVO patients undergoing anti-VEGF therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD 420251011228.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1663350","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:40:02Z","timestamp":1765348802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of anti-VEGF therapy on choroidal thickness in patients with retinal vein occlusion: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiner","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/IAE.0000000000000843","article-title":"Retinal vein occlusions, from basics to the latest treatment.","volume":"36","author":"Ho","year":"2016","journal-title":"Retina."},{"key":"B2","doi-asserted-by":"publisher","first-page":"910600","DOI":"10.3389\/fmed.2022.910600","article-title":"Review: the development of risk factors and cytokines in retinal vein occlusion.","volume":"9","author":"Tang","year":"2022","journal-title":"Front Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00417-020-04983-3","article-title":"Choroidal thickening in retinal vein occlusion patients with serous retinal detachment.","volume":"259","author":"Chen","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/life11060572","article-title":"Subfoveal choroidal thickness and treatment outcomes of intravitreal aflibercept for branch retinal vein occlusion.","volume":"11","author":"Sakanishi","year":"2021","journal-title":"Life."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1186\/s12886-019-1143-9","article-title":"Comparison of subfoveal choroidal thickness in patients with Crvo and Brvo.","volume":"13","author":"Kataria","year":"2023","journal-title":"Eur J Cardiovasc Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102687","DOI":"10.1016\/j.pdpdt.2021.102687","article-title":"The effect of branch retinal vein occlusion on the vascular structure of the choroid.","volume":"37","author":"Alis","year":"2022","journal-title":"Photodiagnosis Photodyn Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2147\/DDDT.S351683","article-title":"Changes of optical coherence tomography biomarkers in macular edema secondary to retinal vein occlusion after anti-vegf and anti-inflammatory therapies.","volume":"16","author":"Ding","year":"2022","journal-title":"Drug Des Devel Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.sjopt.2014.02.004","article-title":"Retino-choroidal ischemia in central retinal vein occlusion.","volume":"28","author":"Hussain","year":"2014","journal-title":"Saudi J Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ajo.2015.05.003","article-title":"Choroidal maps in different types of macular edema in branch retinal vein occlusion using swept-source optical coherence tomography.","volume":"160","author":"Shin","year":"2015","journal-title":"Am J Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.18240\/ijo.2016.05.16","article-title":"Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion.","volume":"9","author":"Coban-Karatas","year":"2016","journal-title":"Int J Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.14744\/bej.2019.40412","article-title":"Long-term results of ranibizumab, dexamethasone implant, and triamcinolone in macular edema due to branch retinal vein occlusion.","volume":"4","author":"Dikel","year":"2019","journal-title":"Beyoglu Eye J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1007\/s00417-024-06562-2","article-title":"Investigation of choroidal structure changes after intravitreal anti-vegf therapy for retinal vein occlusion.","volume":"262","author":"Dursun","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3390\/diagnostics14202328","article-title":"Baseline choroidal blood flow imbalance as a predictive factor for macular edema recurrence secondary to branch retinal vein occlusion.","volume":"14","author":"Hashimoto","year":"2024","journal-title":"Diagnostics."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.3390\/diagnostics14222484","article-title":"Influence of aflibercept on choroidal blood flow and thickness in branch retinal vein occlusion: a six-month follow-up study.","volume":"14","author":"Hashimoto","year":"2024","journal-title":"Diagnostics."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1038\/s41598-023-30239-1","article-title":"Long-term changes in the choroidal thickness in patients with unilateral central retinal vein occlusion.","volume":"13","author":"Hwang","year":"2023","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000504754","article-title":"Long-term follow-up changes of central choroidal thickness thinning after repeated anti-vegf therapy injections in patients with central retinal vein occlusion-related macular edema with systemic hypertension.","volume":"243","author":"Kida","year":"2020","journal-title":"Ophthalmologica."},{"key":"B18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1755-3768.2015.0516","article-title":"Effect of intravitreal bevacizumab on choroidal thickness in eyes with retinal vein occlusion and diabetic macular oedema.","volume":"93","author":"Kuoliene","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.18240\/ijo.2016.07.11","article-title":"Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness.","volume":"56","author":"Lee","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/IAE.0000000000003362","article-title":"Relationship between choroidal findings and growth factors, cytokines, and other inflammatory mediators after intravitreal ranibizumab injection in patients with macular edema secondary to branch retinal vein occlusion.","volume":"42","author":"Noma","year":"2022","journal-title":"Retina."},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ajo.2016.08.026","article-title":"Baseline choroidal thickness as a predictor for treatment outcomes in central retinal vein occlusion.","volume":"171","author":"Rayess","year":"2016","journal-title":"Am J Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000437276","article-title":"Regional choroidal thickness changes in branch retinal vein occlusion with macular edema.","volume":"234","author":"Kim","year":"2015","journal-title":"Ophthalmologica."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/IAE.0000000000001703","article-title":"Clinical findings of eyes with macular edema associated with branch retinal vein occlusion refractory to Ranibizumab.","volume":"38","author":"Hasegawa","year":"2018","journal-title":"Retina."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0258728","DOI":"10.1371\/journal.pone.0258728","article-title":"Role of the choroidal vascularity index in branch retinal vein occlusion (Brvo) with Macular Edema.","volume":"16","author":"Hwang","year":"2021","journal-title":"PLoS One."},{"key":"B25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000496195","article-title":"Microvascular retinal and choroidal changes in retinal vein occlusion analyzed by two different optical coherence tomography angiography devices.","volume":"242","author":"Costanzo","year":"2019","journal-title":"Ophthalmologica."},{"key":"B26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12886-024-03298-9","article-title":"Characteristics of macular edema associated with retinal vein occlusion showing poor anatomic response to three loading anti-vascular endothelial growth factor injections: an optical coherence tomography analysis.","volume":"24","author":"Johari","year":"2024","journal-title":"BMC Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1007\/s10792-021-01798-x","article-title":"Aqueous humor inflammatory cytokine levels and choroidal thickness in patients with macular edema associated with branch retinal vein occlusion.","volume":"41","author":"An","year":"2021","journal-title":"Int Ophthalmol."},{"key":"B28","first-page":"5446","article-title":"Longitudinal changes in choroidal thickness in branch retinal vein occlusion with and without cystoid macular Edema.","volume":"59","author":"Kim","year":"2018","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.2147\/opth.S379373","article-title":"Peripapillary and subfoveal choroidal thickness in retinal vein occlusions.","volume":"16","author":"Moleiro","year":"2022","journal-title":"Clin Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41598-023-27753-7","article-title":"Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion.","volume":"13","author":"Aljundi","year":"2023","journal-title":"Sci Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1007\/s00417-024-06562-2","article-title":"Investigation of choroidal structure changes after intravitreal anti-vegf therapy for retinal vein occlusion.","volume":"262","author":"Dursun","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/bjophthalmol-2018-311898","article-title":"Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion.","volume":"103","author":"Rayess","year":"2019","journal-title":"Br J Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12886-022-02685-4","article-title":"Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study.","volume":"22","author":"Kishishita","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.18240\/ijo.2016.07.11","article-title":"Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion.","volume":"9","author":"Park","year":"2016","journal-title":"Int J Ophthalmol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1663350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:40:04Z","timestamp":1765348804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1663350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":34,"alternative-id":["10.3389\/fmed.2025.1663350"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1663350","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1663350"}}